Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Peab builds top modern swimming pool facility in Kiruna

Peab has been commissioned to build a new swimming pool facility in the new Kiruna City Center. The customer is Kiruna Municipality through WeGroup EPCM Projekt and the contract is worth SEK 290 million.The new facility, which will replace Kiruna’s existing swimming pool, will be two stories high for a total of 10,500 m2 and contain all of 14 pools. The pools will run from two 25 meter exercise pools to multi-pools that have height adjustable bottoms to play pools to family pools. The new swimming pool facility will also have a relax section with a lounge area, warm and cold pools and a so-

Invitation to Kungsleden’s presentation of interim report for January–June 2020

On Wednesday, 8 July 2020, at 7:00 a.m. (CEST), Kungsleden AB (publ) will publish its interim report for January–June 2020. The interim report will be presented via telephone conference and audio broadcast at 8:45 a.m. (CEST)Kungsleden invites investors, asset managers, financial analysts and the press to a presentation of the interim report, where CEO Biljana Pehrsson and Deputy CEO/CFO Ylva Sarby Westman will comment on the report. The report will be published at 7:00 a.m. and will be available to download at https://www.kungsleden.se/en/investors/reports-and-presentations/

Mentice receives order of total SEK 6.0 million from Abbott EP

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Abbott EP for the segment Medical Device Industry. The order covers system sales and development to be delivered during the third quarter 2020. The total order value amounts to SEK 6.0 million and will be accounted for in the order book for the second quarter 2020. The order covers development of additional functionality and the delivery of a global fleet of ultraportable simulators for internal and physician education to be

Orkla ASA: Invitation to presentation of Orkla’s second quarter 2020 results, Monday 13 July

Orkla will report its second quarter 2020 results on Monday, 13 July 2020 at 7.00 a.m. CET. The quarterly report and the presentation material will be available at this time at www.orkla.com.The results will be presented in a webcast with Presidet & CEO Jaan Ivar Semlitsch and CFO Harald Ullevoldsæter at 8.00 a.m. CET. As a consequence of the Corona situation, there will not be a physical presentation of the results. The presentation and subsequent Q&A session will be held in English and may be viewed live at www.orkla.com (direct link: https://events.webcast.no/orkla-asa/

Annual result 2019: Strong growth and a larger geographic footprint

June 29, 2020: 2019 was a strong year for GlobalConnect. The company announced a merger with IP-Only, expanded the fiber network to a total of 74,500 km and invested in services enabling value-adding services such as SD-WAN and managed LAN. The new GlobalConnect/IP-Only group had a total revenue* of 547 million EUR in 2019 whilst investing 381 million EUR.During 2019, GlobalConnect has invested in network and solutions to strengthen its position as the number one challenger offering end-to-end connectivity solutions to businesses and consumers across Northern Europa. From 2020, the combined

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome

SynAct Pharma AB ("SynAct") today announced that the company has initiated a Phase II clinical study with the AP1189 compound in idiopathic membranous nephropathy patients with Nephrotic Syndrome.In the Phase IIa study, AP1189 will be tested in a double-blind, placebo-controlled multicentre study as add-on therapy to ACE-inhibitor or Angiotensin-2 receptor antagonists in a once-daily dose regimen for four weeks with the primary purpose to show treatment effect on urinary protein excretion relative to pre-treatment levels and placebo. The patients will be dosed with either 100 mg AP1189 or

Planmeca decreases patient doses for 3D images of the head – algorithms provide more detailed imaging and diagnostics

Planmeca has developed smart technologies that help decrease the amount of radiation required to produce medical images without compromising the diagnostic quality of the images. The algorithms developed for 3D imaging help produce more detailed images and diagnostics than ever before.Low-dose imaging is beneficial for any patient, but it is particularly significant for children, as a child’s body has comparably more radiation-sensitive red bone marrow than the body of an adult. When new scientific studies on the subject were published around a decade ago, Planmeca began to develop its

MPC Container Ships ASA announces extraordinary general meeting

NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, NEW ZEALAND, SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.Oslo, 29 June 2020 Notice of extraordinary general meeting: MPC Container Ships ASA (the "Company") hereby calls for an extraordinary general meeting in the Company to be held on 13 July at 12:00 hours (CEST) by electronic means. The notice is

Skanska builds school in Lund, Sweden, for SEK 630 M

Skanska has signed a contract with the municipality of Lund to build the Hedda Anderssongymnasiet in Lund. The contract is worth SEK 630 M, which will be included in the order bookings for Sweden for the second quarter 2020.Hedda Anderssongymnasiet is a high school that will seat 2,200 students. The building has a total area of approximately 25,000 square meters and will be four floors high. Construction will begin in late June 2020 by demolition of the current school. The new school is scheduled for completion in the second quarter of 2023. Skanska is one of the leading development-

Nordic Nanovector’s Betalutin® Receives Fast-Track Designation from US FDA for Marginal Zone Lymphoma

Oslo, Norway, 29 June 2020 Nordic Nanovector ASA (OSE: NANO) today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation for investigating Betalutin® ([177]Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior systemic therapies. Nordic Nanovector is evaluating the opportunity to develop Betalutin® as a single-agent treatment for MZL, a rare type of non-Hodgkin’s lymphoma (NHL). Betalutin® has demonstrated a very promising clinical effect in nine

Atea earns platinum-level award for sustainability

Atea ASA (OSE stock ticker: ATEA) has been awarded the highest rating in environmental and social performance by EcoVadis, a highly respected evaluator of supplier sustainability. This achievement ranks Atea in the top 1% of all suppliers evaluated under a collaborative platform used by more than 65,000 companies today. This latest achievement follows after Atea earned for three successive years EcoVadis’s gold-level ranking. To rate and monitor supplier sustainability, EcoVadis assesses corporate social-responsibility performance, covering 150 purchasing categories in 110 countries. Its

Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

Press Release June 29,2020 Oblique Therapeutics and Targovax enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms  · Oblique Therapeutics and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot[TM] technology platforms · ONCOS will be used to deliver Abiprot[TM] antibodies against hard-to-reach targets such as mutant RASGothenburg, Sweden & Oslo, Norway,June 29 2020 – Oblique Therapeutics today announces that it has entered into a collaboration agreement with Targovax ASA (OSE: TRVX)

Targovax and Oblique enter collaboration to target mutant RAS cancers by combining their ONCOS and Abiprot™ platforms

· Targovax and Oblique will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot technology platforms · ONCOS will be used to deliver Abiprot antibodies against hard-to-reach targets such as mutant RAS Oslo, Norway, & Gothenburg, Sweden 29 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that it has entered into a collaboration agreement with Oblique Therapeutics to evaluate the potential of using ONCOS oncolytic adenoviruses as a

Picosun’s medical ALD solutions ensure excellent hermetic encapsulation

ESPOO, Finland, 29[th] June 2020 – Picosun Group reports excellent results in ALD-organic bilayer encapsulation of metal electrodes for neuroprosthetics and bioelectronic medicine. Group also reports superior hermetic barrier performance of its ALD nanolaminates against corrosive ion diffusion in aqueous media. This is an important result for medical ALD applications and implantology, where metal components and sensitive microelectronics need to be protected against corrosion caused by human body fluids. Picosun’s ALD nanolaminates were proven to completely block the diffusion of Na[+],

Cabonline investor presentation

Cabonline will host an investor presentation, currently scheduled for Tuesday June 30, 2020, and ahead of such investor presentation Cabonline will publish a company presentation on Monday June 29, 2020.Cabonline Group Holding AB (publ) (the "Company") will host an investor presentation, currently scheduled for 10.00 CET, Tuesday June 30, 2020. Ahead of the investor presentation, the Company will publish a company presentation on Monday June 29, 2020, including certain information regarding the interim period April – June, 2020. The company presentation will be available on the Company’s

President and CEO Fredrik Gren to leave Ambea

Ambea’s President and CEO Fredrik Gren has informed the board of directors that he is leaving the company. Fredrik Gren will remain in his current position until year end and the board of directors will now begin the recruitment of a successor.After almost nine year at Ambea, Fredrik Gren has decided to leave his position as President and CEO of the company. ‒ I am proud of Ambea’s development and grateful for the opportunity to work with all of Ambea’s dedicated and competent employees. Ambea is an amazing company with an important role in society to provide care for children, adults,

Independent travel agent welcomes back customers as holiday bookings surge

A POPULAR independent travel agent is reopening its offices as holiday bookings surge now restrictions are set to be lifted.  The government is due to announce this week the opening of quarantine-free air corridors to at least 15 countries from July 6.  Those countries are expected to include Spain, France, Italy, Greece, the Netherlands, Finland, Belgium, Turkey, Germany, Croatia and Norway.  Holidaymakers choosing a getaway to those destinations named as air corridors  will not have to spend 14 days in quarantine on their return to Britain.  Following news of this easing

Keep viruses and bacteria out of drinking water with reverse osmosis

With the growing awareness of the health risks posed by bacteria and virus, customers are seeking information on how to keep their drinking water safe from waterborne pathogens. The best method for doing this in household water purification is by using reverse osmosis technology.While there is no evidence of COVID-19 infection through drinking water and the risk of COVID-19 transmission through water is considered to be low, it is only natural for consumers to want to keep waterborne bacteria, viruses and other microorganisms  

polight asa – resolution to increase the share capital

poLight ASA (the "Company") has a general share option scheme, whereby share options in the Company are granted to all employees. The Company has received notices of exercise of 20 689 share options, including those share options exercised by Pierre Craen as disclosed on 23 May 2020. 9 444 of the share options hold an exercise price of NOK 50 per option, 28 of the share options hold an exercise price of NOK 27 and 11 217 of the share options hold an exercise price of NOK 18.90. The Board of Directors has today resolved a share capital increase of NOK 4 137,80 through issuance of 20

Notice to extraordinary General Meeting in ITAB Shop Concept AB (publ)

The shareholders in ITAB Shop Concept AB (publ), Reg.No. 556292-1089, with its registered office in Jönköpings county, are hereby summoned to an extraordinary general meeting to be held on 22 July 2020.Due to the extraordinary situation resulting from the covid-19 pandemic, the extraordinary general meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Preconditions for participation in the extraordinary general meeting Shareholders who

Correction: Previous press release had an incorrect MAR reference.

First Berlin Equity Research publishes independent analysis of Cyxone Cyxone (publ), a Swedish biotech in autoimmune diseases, announces today that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first quarter of 2020 and was published on 26 June 2020, where First Berlin reviewed the company’s potential with an expected but continued positive outcome. The report in English can be read in its entirety on the Cyxone’s website. ContactTara Heitner, CEOTel: +46 70

Bulletin from the Annual General Meeting in EWPG Holding AB (publ)

June 26, 2020 – The annual general meeting in EWPG Holding AB (publ) was held on Friday 26 June 2020. The following resolutions, amongst others, were passed at the general meeting that was held by, and limited to, postal voting.Adoption of the income statements and balance sheets, disposal of result, and resolution regarding discharge of liabilityThe annual general meeting resolved to adopt the income statement and balance sheet and the group’s income statement and balance sheet for the financial year of 2019. The annual general meeting resolved, in accordance with the board of

#20-223 Delisting of certain Derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

There are no items matching the current filter
There are no more items matching the current filter
Back to top